PureTech reports FDA Phase 1 end-of-phase meeting success
PureTech says it completed an FDA End-of-Phase 1 meeting and received Fast Track designation for LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS).
Story updates
06:00:55 AM UTC
SquawkNews
PureTech completed an FDA End-of-Phase 1 meeting and received Fast Track for LYT-200 with an HMA in R/R high-risk MDS, enabling a randomized Phase 2 trial. The company plans to use external capital and expects to secure funding in H1 2027.Material DetailsContext by AI AnalystThis is an early-to-mid…
S. Food and Drug Administration.